IN2014CN03072A - - Google Patents

Info

Publication number
IN2014CN03072A
IN2014CN03072A IN3072CHN2014A IN2014CN03072A IN 2014CN03072 A IN2014CN03072 A IN 2014CN03072A IN 3072CHN2014 A IN3072CHN2014 A IN 3072CHN2014A IN 2014CN03072 A IN2014CN03072 A IN 2014CN03072A
Authority
IN
India
Prior art keywords
compositions
directed
production
methods
present
Prior art date
Application number
Other languages
English (en)
Inventor
Terrance A Stadheim
Daniel Cua
Dongxing Zha
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of IN2014CN03072A publication Critical patent/IN2014CN03072A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
IN3072CHN2014 2011-10-31 2012-10-26 IN2014CN03072A (enExample)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161553335P 2011-10-31 2011-10-31
PCT/US2012/062211 WO2013066761A1 (en) 2011-10-31 2012-10-26 Method for preparing antibodies having improved properties

Publications (1)

Publication Number Publication Date
IN2014CN03072A true IN2014CN03072A (enExample) 2015-07-31

Family

ID=48192651

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3072CHN2014 IN2014CN03072A (enExample) 2011-10-31 2012-10-26

Country Status (9)

Country Link
US (1) US20140286946A1 (enExample)
EP (1) EP2773661A4 (enExample)
JP (1) JP2014532661A (enExample)
KR (1) KR20140097245A (enExample)
CN (1) CN104011076A (enExample)
AU (1) AU2012332840A1 (enExample)
CA (1) CA2853809A1 (enExample)
IN (1) IN2014CN03072A (enExample)
WO (1) WO2013066761A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11377485B2 (en) 2009-12-02 2022-07-05 Academia Sinica Methods for modifying human antibodies by glycan engineering
US10087236B2 (en) 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
RU2016103373A (ru) 2013-07-04 2017-08-10 Новартис Аг Клетки нитчатых грибов с дефицитом о-маннозилтрансферазы и способы их применения
EP3041484B1 (en) 2013-09-06 2021-03-03 Academia Sinica Human inkt cell activation using glycolipids with altered glycosyl groups
EP3049442A4 (en) 2013-09-26 2017-06-28 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
UA122479C2 (uk) 2014-01-24 2020-11-25 Дана-Фарбер Кенсер Інстітьют, Інк. Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1)
PL3099717T3 (pl) 2014-01-31 2019-10-31 Novartis Ag Cząsteczki przeciwciała dla TIM-3 i ich zastosowanie
EP4116329A1 (en) 2014-05-27 2023-01-11 Academia Sinica Anti-her2 glycoantibodies and uses thereof
KR20170010003A (ko) * 2014-05-27 2017-01-25 아카데미아 시니카 박테로이드 기원의 푸코시다제 및 이의 사용 방법
JP2017518989A (ja) 2014-05-27 2017-07-13 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ 抗ｃｄ２０糖操作抗体群およびその使用
JP7063538B2 (ja) 2014-05-28 2022-05-09 アカデミア シニカ 抗ＴＮＦα糖操作抗体群およびその使用
AU2015293949B2 (en) 2014-07-21 2019-07-25 Teknologian Tutkimuskeskus Vtt Oy Production of glycoproteins with mammalian-like N-glycans in filamentous fungi
JO3663B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
EP3191126B1 (en) 2014-09-13 2020-05-13 Novartis AG Combination therapies of alk inhibitors
US20180340025A1 (en) 2015-07-29 2018-11-29 Novartis Ag Combination therapies comprising antibody molecules to lag-3
BR112018012352A2 (pt) 2015-12-16 2018-12-11 Merck Sharp & Dohme Corp. anticorpos anti-lag3 e fragmentos de ligação ao antígeno
CN108495651A (zh) 2015-12-17 2018-09-04 诺华股份有限公司 抗pd-1的抗体分子及其用途
CA3034057A1 (en) 2016-08-22 2018-03-01 CHO Pharma Inc. Antibodies, binding fragments, and methods of use
KR20210084695A (ko) * 2017-07-06 2021-07-07 리제너론 파마슈티칼스 인코포레이티드 당단백질을 만들기 위한 세포 배양 과정

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080206246A1 (en) * 2006-04-05 2008-08-28 Ravetch Jeffrey V Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
CA2655246A1 (en) * 2006-06-09 2007-12-21 University Of Maryland, Baltimore Glycosylation engineered antibody therapy
FR2912154B1 (fr) * 2007-02-02 2012-11-02 Glycode Levures genetiquement modifiees pour la production de glycoproteines homogenes
AU2011258425B2 (en) * 2010-05-27 2015-12-10 Merck Sharp & Dohme Llc Method for preparing antibodies having improved properties

Also Published As

Publication number Publication date
AU2012332840A1 (en) 2014-05-15
JP2014532661A (ja) 2014-12-08
WO2013066761A1 (en) 2013-05-10
EP2773661A4 (en) 2015-06-17
US20140286946A1 (en) 2014-09-25
CN104011076A (zh) 2014-08-27
CA2853809A1 (en) 2013-05-10
KR20140097245A (ko) 2014-08-06
EP2773661A1 (en) 2014-09-10

Similar Documents

Publication Publication Date Title
PH12014501427B1 (en) Anti-phf-tau antibodies and their uses
JOP20180103A1 (ar) مركب صيدلاني
MX2015006324A (es) Metodos para la fabricacion de polipeptidos proteoliticamente procesados.
MX2018010572A (es) Inmunoglobulinas heterodimericas.
IN2013MN00501A (enExample)
MX2022000026A (es) Anticuerpos para tau.
IN2015DN00127A (enExample)
IN2015DN03029A (enExample)
MY177031A (en) Tetrahydropyridopyrazines modulators of gpr6
MX337549B (es) Derivados de insulina que contienen enlaces disulfuro adicionales.
PL3027726T3 (pl) Poprawiona fermentacja substratów gazowych
IN2015DN00372A (enExample)
MX2013000793A (es) Composicion que contiene galacto-oligosacarido y un metodo para producirla.
IN2014DN09450A (enExample)
MX2011012623A (es) Construcciones de casb7439.
IN2014DN00254A (enExample)
MX347541B (es) Analogos de acido sialico.
IN2013MU01113A (enExample)
WO2013181599A3 (en) Methods related to rituximab
PH12016501201A1 (en) Synthesis of ent-progesterone and intermediates thereof
MX2013014420A (es) Composiciones en gel.
IN2013MU01290A (enExample)
MX2015012902A (es) Sintesis de ent-progesterona e intermediarios de la misma.
MX337610B (es) Proceso para la preparacion de (r)-2-acetamido-n-bencil-3-metoxipr opionamida e intermediarios de la misma.
MX391523B (es) Intermediarios y metodos para sintetizar derivados de calicheamicina